A randomized, double-blind, placebo-controlled Phase I trial analysing safety of CIN-103 in healthy volunteers
Latest Information Update: 10 Aug 2022
At a glance
- Drugs CIN-103 (Primary)
- Indications Irritable bowel syndrome
- Focus Adverse reactions
- 10 Aug 2022 Status changed from planning to completed.
- 19 Apr 2021 New trial record